4.7 Article

Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers

Journal

NEUROLOGY
Volume 77, Issue 4, Pages 325-333

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318227042d

Keywords

-

Funding

  1. Merck Serono
  2. National Parkinson Foundation
  3. Parkinson Study Group
  4. Parkinson Disease Foundation
  5. Michael J Fox Foundation
  6. Canadian Institutes of Health Research
  7. California Institute for Regenerative Medicine
  8. Blume Foundation
  9. Parkinson's Alliance
  10. Ontario Research Fund
  11. US Department of Defense
  12. NIH/NIEHS
  13. The Blume Foundation/Stanford University
  14. Melvin Yahr Foundation
  15. German Research Foundation (DFG)
  16. University of Lubeck
  17. Volkswagen Foundation
  18. Possehl Foundation
  19. Hermann and Lilly Schilling Foundation
  20. Fritz Thyssen Foundation
  21. University of Malaya
  22. Solvay Pharmaceuticals, Inc.
  23. Dystonia Medical Research Foundation
  24. NIH
  25. Medtronic, Inc.
  26. ZonMw Doelmatigheid
  27. Het Internationaal Parkinson Fonds
  28. Parkinson Vereniging
  29. Het Prinses Beatrix Fonds
  30. Boehringer Ingelheim
  31. Ontario Problem Gambling Research Centre
  32. Edmund J. Safra Philanthropic Association
  33. EU [EU-LSHB-CT-2006-037544]
  34. NGFNplus (BMBF) [PNP-01GS08135-3]
  35. MRC [MC_G1000734] Funding Source: UKRI
  36. Medical Research Council [MC_G1000734] Funding Source: researchfish

Ask authors/readers for more resources

Objectives: Using a family study design, we describe the motor and nonmotor phenotype in probands with LRRK2 G2019S mutations and family members and compare these individuals to patients with idiopathic Parkinson disease (iPD) and unrelated controls. Methods: Probands with G2019S mutations and their first-degree relatives, subjects with iPD, and unrelated control subjects were identified from 4 movement disorders centers. All underwent neurologic examinations and tests of olfaction, color vision, anxiety, and depression inventories. Results: Tremor was more often a presenting feature among 25 individuals with LRRK2-associated PD than among 84 individuals with iPD. Subjects with LRRK2-PD had better olfactory identification compared with subjects with iPD, higher Beck Depression Inventory scores, and higher error scores on Farnsworth-Munsell 100-Hue test of color discrimination. Postural or action tremor was more common among 29 nonmanifesting mutation carriers compared with 53 noncarriers within the families. Nonparkinsonian family members had higher Unified Parkinson's Disease Rating Scale motor scores, more constipation, and worse color discrimination than controls, regardless of mutation status. Conclusions: Although tremor is a more common presenting feature of LRRK2-PD than iPD and some nonmotor features differed in degree, the phenotype is largely overlapping. Postural or action tremor may represent an early sign. Longitudinal evaluation of a large sample of nonmanifesting carriers will be required to describe any premotor phenotype that may allow early diagnosis. Neurology (R) 2011; 77: 325-333

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available